KLK3 and neoplasm: However, when a patient experiences tumor metastasis or uncontrolled prostate-specific antigen (PSA) levels, the tumor may develop hormone resistance, resulting in resistance to ADT agents and a decline in the 5-year survival rate to approximately 30%.